Margaux Arntson

Cooley advised Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its $375 million capital return program, which represents the culmination of Keros’ strategic review process, including its share purchase agreements to repurchase all shares of its common stock beneficially owned by ADAR1 Capital Management and Pontifax Venture Capital and planned tender offer for up to $194 million in value of shares of its common stock.

Cooley advised Michael Horvath, co-founder and former CEO of Strava, on his lead seed round investment in FeMMA, a new app connecting women through martial arts.

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

Cooley advised Xometry, the global artificial intelligence-powered marketplace connecting buyers with suppliers of manufacturing services, on its $250 million aggregate principal amount of 0.75% convertible senior notes due 2030, which includes the initial purchasers’ option to purchase up to an additional $25 million aggregate principal amount of notes.

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.